Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Other Non-Current Assets (2016 - 2025)

Rocket Pharmaceuticals' Other Non-Current Assets history spans 10 years, with the latest figure at $482000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets fell 8.88% year-over-year to $482000.0; the TTM value through Dec 2025 reached $482000.0, down 8.88%, while the annual FY2025 figure was $482000.0, 8.88% down from the prior year.
  • Other Non-Current Assets for Q4 2025 was $482000.0 at Rocket Pharmaceuticals, down from $515000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $608000.0 in Q4 2022 and bottomed at $455000.0 in Q1 2021.
  • The 5-year median for Other Non-Current Assets is $492500.0 (2024), against an average of $497050.0.
  • The largest annual shift saw Other Non-Current Assets skyrocketed 33.63% in 2022 before it decreased 12.34% in 2023.
  • A 5-year view of Other Non-Current Assets shows it stood at $455000.0 in 2021, then skyrocketed by 33.63% to $608000.0 in 2022, then fell by 12.34% to $533000.0 in 2023, then dropped by 0.75% to $529000.0 in 2024, then decreased by 8.88% to $482000.0 in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Other Non-Current Assets are $482000.0 (Q4 2025), $515000.0 (Q3 2025), and $515000.0 (Q2 2025).